Quince Therapeutics (QNCX) Stock: Buy, Sell, or Hold?
QNCX - Quince Therapeutics, Inc. Common Stock
$29.20
-1.48 (-4.82%)
▼
5d:
-5.81%
30d:
-9.18%
90d:
+71.97%
HOLD
MODERATE Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 11, 2026
Get Alerted When QNCX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: QNCX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: QNCX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: QNCX is currently trading at $29.20, which is considered slightly low relative to its 30-day fair value range of $28.86 to $31.94.
Technical Outlook: Technically, QNCX is in a strong uptrend. Immediate support is located at $26.45, while resistance sits at $32.99. Short-term momentum is weak, with the stock down 4.8% recently.
Market Sentiment: QNCX scores 37/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $75.43 (+158.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, QNCX is in a strong uptrend. Immediate support is located at $26.45, while resistance sits at $32.99. Short-term momentum is weak, with the stock down 4.8% recently.
Market Sentiment: QNCX scores 37/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $75.43 (+158.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$28.86 -
$31.94
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (37/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.8%)
- BULLISH: Trading 158.3% below Wall St target ($75.43)
- CAUTION: 5-day price weakness (-5.8%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$28.86 -
$31.94
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$26.45
Resistance Level
$32.99
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.23
Wall Street Target
$75.43
(+158.3%)
Share & Embed Analysis
Last updated: October 03, 2026 9:58 PM ET
Data refreshes hourly during market hours. Next update: 10:58 PM
Data refreshes hourly during market hours. Next update: 10:58 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is QNCX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$92 | 46 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 76 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 65 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 42 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$128 | 56 HOLD |
